RadioMedix and Orano Med complete patient enrolment for neuroendocrine cancer trial

May 16, 2023
Medical Communications Oncology, Orano Med, RadioMedix, neuroendocrine cancer, oncology

US-based RadioMedix and French Orano Med, two clinical stage radiopharmaceutical companies, have announced that the last patient has been enrolled …

Nido Biosciences raises $109m in funding for neurological diseases treatments

May 16, 2023
Sales and Marketing Financing, Neurology, Nido Biosciences, funding, neurology

US-based clinical-stage company Nido Biosciences has announced that is has received $109m in Seed, Series A and Series B financings, …

Astellas and Sony enter collaborative research agreement

May 16, 2023
Research and Development ADC, Astellas Pharma, Oncology, Sony, research agreement

Sony and Astellas Pharma have announced that they have entered into a collaborative research agreement in an attempt to discover …

uniQure announces sale of royalty interest in Hemgenix for up to $400m

May 16, 2023
Sales and Marketing Haematology, Hemgenix, haemophilia, royalties, uniQure

uniQure has announced that it has entered a definitive agreement to sell a portion of the royalty rights due to …

LaNova Medicines and AstraZeneca sign global exclusive license agreement for preclinical ADC

May 15, 2023
Research and Development ADC, AstraZeneca, LaNova Medicines, License Agreement, Oncology

Chinese biotechnology company LaNova Medicines and UK-based pharma company AstraZeneca have announced that they have signed a global exclusive license …

Relief Therapeutics awarded approval from Swissmedic for new GMP-compliant laboratory

May 15, 2023
Research and Development GMP, Relief Therapeutics, Swissmedic, laboratory

Swiss biopharmaceutical company Relief Therapeutics has announced that its state-of-the-art R&D laboratory in Balerna, Switzerland, has been audited and approved …

NICE recommends Hepcludex for NHS use to treat aggressive form of viral hepatitis

May 15, 2023
Medical Communications NHS, NICE, Virology, hepatitis

The National Institute for Health and Care Excellence (NICE) has recommended Hepcludex (bulevirtide) for the treatment of chronic hepatitis delta …

hal-gatewood-_jbclosdsd4-unsplash

FDA approves new nonhormonal medication for menopause hot flashes

May 15, 2023
Medical Communications FDA, HRT, Veozah, hot flashes, menopause

The US Food and Drug Administration (FDA) has announced its approval of Veozah (fezolinetant), an oral medication to treat moderate …

FDA relaxes blood donation regulations for MSM

May 12, 2023
Medical Communications FDA, HIV, HIV/AIDS, blood donation

The US Food and Drug Administration (FDA) has released updated guidance for blood donation which relaxes the rules for donations …

robina-weermeijer-ihfopazzjhm-unsplash_5

Angelini Pharma and JCR Pharmaceuticals partner to develop new epilepsy therapies

May 12, 2023
Sales and Marketing Angelini Pharma, JCR Pharmaceuticals, Neurology, epilepsy

Angelini Pharma and JCR Pharmaceuticals have announced that they have entered into an exclusive global development and commercialisation agreement for …

Bellerophon Therapeutics completes phase 3 study for fibrotic interstitial lung disease drug

May 12, 2023
Medical Communications Bellerophon Therapeutics, Cardiology, clinical trial, lung disease

US clinical stage biotherapeutics company Bellerophon Therapeutics has announced that the last patient has completed its phase 3 REBUILD study, …

FDA advisory committee votes in support of favourable benefit-risk profile for ARS Pharmaceuticals’ allergic reaction treatment

May 12, 2023
Research and Development ARS Pharmaceuticals, Allergic Disorders, FDA, allergy

US-based biopharmaceutical company ARS Pharmaceuticals has announced that the US Food and Drug Administration (FDA)’s Pulmonary-Allergy Drug Advisory Committee (PADAC) …

FDA advisory committee votes in favour of OTC contraceptive pill

May 11, 2023
Medical Communications Contraception, FDA, OTC, Perrigo, contraception

Perrigo Company has announced that the US Food and Drug Administration’s (FDA) Nonprescription Drugs Advisory Committee (NDAC) and the Obstetrics, …

Otsuka and Lundbeck gain FDA approval for supplemental New Drug Application for dementia drug

May 11, 2023
Medical Communications FDA, Lundbeck, Neurology, Otsuka Pharmaceuticals, alzheimer's disease, dementia

Japan-based healthcare company Otsuka Pharmaceutical and Danish pharma company Lundbeck have announced that the US Food and Drug Administration (FDA) …

AstraZeneca’s Ultomiris approved in EU for adults firm NMOSD

May 11, 2023
Medical Communications AstraZeneca, NMOSD, Neurology, Ultomiris, neurology

AstraZeneca has announced the approval of Ultomiris (ravulizumab) in the European Union (EU) for the treatment of adult patients with …

Gilead acquires XinThera to strengthen pipeline in oncology and inflammation

May 10, 2023
Sales and Marketing Gilead, Oncology, XinThera, inflammation, oncology

Gilead Sciences has announced the acquisition of all outstanding shares of XinThera, a privately-owned biotech company based in San Diego, …

Eyenovia announces FDA approval of first ophthalmic spray for mydriasis

May 10, 2023
Research and Development Eyenovia, FDA, Opthalmology, mydriasis, ophthalmology

Ophthalmic technology company Eyenovia has announced that the US Food and Drug Administration (FDA) has approved Mydcombi (tropicamide and phenylephrine …

Sobi acquires CTI BioPharma Corporation for $1.7bn

May 10, 2023
Medical Communications CTI, acquisition, sobi

Swedish Orphan Biovitrum, aka Sobi, has announced that it had entered into a ‘plan of merger’ with CTI BioPharma Corp …

Thermo Fisher and Pfizer collaborate on NGS-based cancer tests

May 10, 2023
Medical Communications Cancer, NGS, Oncology, Pfizer, Thermo Fisher Scientifitic, oncology

Scientific equipment provider Thermo Fisher and US pharmaceutical firm Pfizer have announced a collaboration to advance next-generation sequencing (NGS)-based cancer …

The Gateway to Local Adoption Series

Latest content